Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

WHO Urges H1N1 Vaccine Producers To Give 10 Per Cent To Poor Countries
The World Health Organization (WHO) urged pharmaceutical companies to donate at least 10 per cent of their H1N1 pandemic swine flu vaccine
generic viagra online
÷£100 Million Social Marketing Campaign To Encourage Responsible Drinking Announced, UK
Following Gordon Brown"s meeting at Downing Street with Britain"s top drinks industry executives he called for them to harness their considerable marketing powers to drive for change in social norm and cultural attitudes towards alcohol in the UK. This has resulted in Project "N" - a collaboration of the not inconsiderable res of top companies throughout the UK.
News of the day
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) In Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
Public Health

MAGI's 2009 Clinical Research Conference - WEST

If you are a clinical research novice or veteran with a study sponsor, research site, or CRO in a corporate, academic or other organization, you will find a comprehensive program that focuses on your current needs and broadens your knowledge. MAGI conferences feature balanced co-presentations from sponsors, sites and CROs, real-life examples, practical tips, and lots of interaction and networking. This year"s conference will feature: - 400+ participants from sponsors, sites, and CROs - 150+ speakers - 80+ sessions in 6 tracks: contracts, budgets and billing, regulatory and ethics, sponsor operations, site operations, and special topics - Complimentary interactive pre- and post-conference workshops - Exceptional networking environment and activities - 20+ nursing continuing education (CNE) credits - Clinical Research Contract Professional (CRCP) certification exam MAGI


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009